{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:53Z","timestamp":1793145293510,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Young Elite Scientists Sponsorship Program by CACM","award":["2021-QNRC2-B13"],"award-info":[{"award-number":["2021-QNRC2-B13"]}]},{"name":"the National undergraduate innovation and entrepreneurship training program","award":["202210344039"],"award-info":[{"award-number":["202210344039"]}]},{"name":"the Research Project Funding of Zhejiang Chinese Medical University","award":["2022FSYYZY07"],"award-info":[{"award-number":["2022FSYYZY07"]}],"id":[{"id":"https:\/\/ror.org\/04epb4p87","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68311-z","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:01:49Z","timestamp":1727438509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Antibody\u2013drug conjugates and immune checkpoint inhibitors in cancer treatment: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Leyin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yici","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leitao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"68311_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"68311_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","volume":"109","author":"DR Goulet","year":"2020","unstructured":"Goulet, D. R. & Atkins, W. M. Considerations for the design of antibody-based therapeutics. J. Pharm. Sci. 109, 74\u2013103. https:\/\/doi.org\/10.1016\/j.xphs.2019.05.031 (2020).","journal-title":"J. Pharm. Sci."},{"key":"68311_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z. et al. Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target Ther. 7, 93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"68311_CR4","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/s1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas, A., Teicher, B. A. & Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 17, e254\u2013e262. https:\/\/doi.org\/10.1016\/s1470-2045(16)30030-4 (2016).","journal-title":"Lancet Oncol."},{"key":"68311_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K. et al. Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223. https:\/\/doi.org\/10.1038\/s41571-023-00850-2 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68311_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122898","author":"C Corti","year":"2021","unstructured":"Corti, C. et al. Antibody-drug conjugates for the treatment of breast cancer. Cancers https:\/\/doi.org\/10.3390\/cancers13122898 (2021).","journal-title":"Cancers"},{"key":"68311_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.urolonc.2022.07.006","volume":"40","author":"TC Padua","year":"2022","unstructured":"Padua, T. C. et al. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review. Urol. Oncol. 40, 413\u2013423. https:\/\/doi.org\/10.1016\/j.urolonc.2022.07.006 (2022).","journal-title":"Urol. Oncol."},{"key":"68311_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050803","author":"A Ungaro","year":"2022","unstructured":"Ungaro, A. et al. Antibody-drug conjugates in urothelial carcinoma: A new therapeutic opportunity moves from bench to bedside. Cells https:\/\/doi.org\/10.3390\/cells11050803 (2022).","journal-title":"Cells"},{"key":"68311_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188549","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. HER2-targeted therapies in gastric cancer. Biochim. Biophys. Acta Rev. Cancer 1876, 188549. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188549 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"68311_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041551","author":"M Rosellini","year":"2021","unstructured":"Rosellini, M. et al. Treating prostate cancer by antibody-drug conjugates. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22041551 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"68311_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar, A. et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed. Pharmacother. 161, 114408. https:\/\/doi.org\/10.1016\/j.biopha.2023.114408 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"68311_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"68311_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40265-023-01884-7","volume":"83","author":"KC Retifanlimab","year":"2023","unstructured":"Retifanlimab, K. C. First approval. Drugs 83, 731\u2013737. https:\/\/doi.org\/10.1007\/s40265-023-01884-7 (2023).","journal-title":"Drugs"},{"key":"68311_CR14","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0055","author":"X Kong","year":"2024","unstructured":"Kong, X. et al. Immune checkpoint inhibitors: Breakthroughs in cancer treatment. Cancer Biol. Med. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0055 (2024).","journal-title":"Cancer Biol. Med."},{"key":"68311_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","volume":"25","author":"H Hayashi","year":"2020","unstructured":"Hayashi, H. & Nakagawa, K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int. J. Clin. Oncol. 25, 818\u2013830. https:\/\/doi.org\/10.1007\/s10147-019-01548-1 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"68311_CR16","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li, B., Chan, H. L. & Chen, P. Immune checkpoint inhibitors: Basics and challenges. Curr. Med. Chem. 26, 3009\u20133025. https:\/\/doi.org\/10.2174\/0929867324666170804143706 (2019).","journal-title":"Curr. Med. Chem."},{"key":"68311_CR17","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G. et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020 (2021).","journal-title":"Cell"},{"key":"68311_CR18","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1535-7163.Mct-19-1102","volume":"19","author":"AO Abu-Yousif","year":"2020","unstructured":"Abu-Yousif, A. O. et al. Preclinical antitumor activity and biodistribution of a novel anti-GCC antibody-drug conjugate in patient-derived xenografts. Mol. Cancer Ther. 19, 2079\u20132088. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-1102 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"68311_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta, L. & Pollard, J. W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887\u2013904. https:\/\/doi.org\/10.1038\/nrd.2018.169 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68311_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s1470-2045(18)30859-3","volume":"20","author":"JS de Bono","year":"2019","unstructured":"de Bono, J. S. et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 383\u2013393. https:\/\/doi.org\/10.1016\/s1470-2045(18)30859-3 (2019).","journal-title":"Lancet Oncol."},{"key":"68311_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1565859","volume":"8","author":"M Bauzon","year":"2019","unstructured":"Bauzon, M. et al. Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology 8, e1565859. https:\/\/doi.org\/10.1080\/2162402x.2019.1565859 (2019).","journal-title":"Oncoimmunology"},{"key":"68311_CR22","doi-asserted-by":"publisher","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","volume":"7","author":"P M\u00fcller","year":"2015","unstructured":"M\u00fcller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade. Sci. Transl. Med. 7, 315ra188. https:\/\/doi.org\/10.1126\/scitranslmed.aac4925 (2015).","journal-title":"Sci. Transl. Med."},{"key":"68311_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1637188","volume":"8","author":"O Kepp","year":"2019","unstructured":"Kepp, O., Zitvogel, L. & Kroemer, G. Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade. Oncoimmunology 8, e1637188. https:\/\/doi.org\/10.1080\/2162402x.2019.1637188 (2019).","journal-title":"Oncoimmunology"},{"key":"68311_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222280","volume":"14","author":"TN Iwata","year":"2019","unstructured":"Iwata, T. N. et al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS ONE 14, e0222280. https:\/\/doi.org\/10.1371\/journal.pone.0222280 (2019).","journal-title":"PLoS ONE"},{"key":"68311_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","volume":"102","author":"HP Gerber","year":"2016","unstructured":"Gerber, H. P. et al. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?. Biochem. Pharmacol. 102, 1\u20136. https:\/\/doi.org\/10.1016\/j.bcp.2015.12.008 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"68311_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2022.2042252","volume":"31","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. et al. Ladiratuzumab vedotin for metastatic triple negative cancer: Preliminary results, key challenges, and clinical potential. Expert Opin. Investig. Drugs 31, 495\u2013498. https:\/\/doi.org\/10.1080\/13543784.2022.2042252 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"68311_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2022.40.6_suppl.434","volume":"40","author":"P Grivas","year":"2022","unstructured":"Grivas, P. et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. J. Clin. Oncol. 40, 434\u2013434. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.434 (2022).","journal-title":"J. Clin. Oncol."},{"key":"68311_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani, R. H. et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 138, 427\u2013438. https:\/\/doi.org\/10.1182\/blood.2020009178 (2021).","journal-title":"Blood"},{"key":"68311_CR29","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1016\/j.clml.2019.07.262","volume":"19","author":"PL Zinzani","year":"2019","unstructured":"Zinzani, P. L. et al. Nivolumab combined with brentuximab vedotin (BV) for relapsed\/refractory primary mediastinal large B-cell lymphoma (R\/R PMBL): Efficacy and safety results from the phase 2 CheckMate 436 study. Clin. Lymphoma Myeloma Leuk. 19, S303. https:\/\/doi.org\/10.1016\/j.clml.2019.07.262 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"68311_CR30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/s1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens, L. A. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21, 1283\u20131295. https:\/\/doi.org\/10.1016\/s1470-2045(20)30465-4 (2020).","journal-title":"Lancet Oncol."},{"key":"68311_CR31","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/s2352-3026(20)30275-1","volume":"7","author":"BD Cheson","year":"2020","unstructured":"Cheson, B. D. et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): A multicentre, single-arm, phase 2 trial. Lancet Haematol. 7, e808\u2013e815. https:\/\/doi.org\/10.1016\/s2352-3026(20)30275-1 (2020).","journal-title":"Lancet Haematol."},{"key":"68311_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.Ccr-21-1181","volume":"28","author":"S Rottey","year":"2022","unstructured":"Rottey, S. et al. Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin. Cancer Res. 28, 95\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1181 (2022).","journal-title":"Clin. Cancer Res."},{"key":"68311_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643","author":"CJ Hoimes","year":"2022","unstructured":"Hoimes, C. J. et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01643 (2022).","journal-title":"J. Clin. Oncol."},{"key":"68311_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040982","author":"F Massaro","year":"2022","unstructured":"Massaro, F. et al. Brentuximab vedotin and pembrolizumab combination in patients with relapsed\/refractory Hodgkin lymphoma: A single-centre retrospective analysis. Cancers https:\/\/doi.org\/10.3390\/cancers14040982 (2022).","journal-title":"Cancers"},{"key":"68311_CR35","doi-asserted-by":"publisher","first-page":"S1441","DOI":"10.1016\/j.annonc.2022.08.079","volume":"33","author":"JE Rosenberg","year":"2022","unstructured":"Rosenberg, J. E. et al. LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC). Ann. Oncol. 33, S1441. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.079 (2022).","journal-title":"Ann. Oncol."},{"key":"68311_CR36","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/jco.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote, I. et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study. J. Clin. Oncol. 41, 5536\u20135549. https:\/\/doi.org\/10.1200\/jco.23.00720 (2023).","journal-title":"J. Clin. Oncol."},{"key":"68311_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal, F. et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Eur. Urol. Oncol. 4, 755\u2013765. https:\/\/doi.org\/10.1016\/j.euo.2021.03.001 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"68311_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100244","volume":"6","author":"EB Ulas","year":"2021","unstructured":"Ulas, E. B. et al. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: A systematic review. ESMO Open 6, 100244. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100244 (2021).","journal-title":"ESMO Open"},{"key":"68311_CR39","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.7150\/jca.49174","volume":"12","author":"X Ma","year":"2021","unstructured":"Ma, X. et al. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review. J. Cancer 12, 1318\u20131333. https:\/\/doi.org\/10.7150\/jca.49174 (2021).","journal-title":"J. Cancer"},{"key":"68311_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103758","volume":"177","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 177, 103758. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103758 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"68311_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1208\/s12248-021-00584-y","volume":"23","author":"D Bussing","year":"2021","unstructured":"Bussing, D. et al. Quantitative evaluation of the effect of antigen expression level on antibody-drug conjugate exposure in solid tumor. AAPS J. 23, 56. https:\/\/doi.org\/10.1208\/s12248-021-00584-y (2021).","journal-title":"AAPS J."},{"key":"68311_CR42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00404-020-05734-9","volume":"302","author":"L Lazzerini","year":"2020","unstructured":"Lazzerini, L. et al. Favorable therapeutic response after anti-mesothelin antibody-drug conjugate treatment requires high expression of mesothelin in tumor cells. Arch. Gynecol. Obstet. 302, 1255\u20131262. https:\/\/doi.org\/10.1007\/s00404-020-05734-9 (2020).","journal-title":"Arch. Gynecol. Obstet."},{"key":"68311_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11864-021-00840-5","volume":"22","author":"X Andrade-Gonzalez","year":"2021","unstructured":"Andrade-Gonzalez, X. & Ansell, S. M. Novel therapies in the treatment of Hodgkin lymphoma. Curr. Treat. Options Oncol. 22, 42. https:\/\/doi.org\/10.1007\/s11864-021-00840-5 (2021).","journal-title":"Curr. Treat. Options Oncol."},{"key":"68311_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-018-0601-9","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. J. Hematol. Oncol. 11, 57. https:\/\/doi.org\/10.1186\/s13045-018-0601-9 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"68311_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094774","author":"A Indini","year":"2021","unstructured":"Indini, A., Rijavec, E. & Grossi, F. Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22094774 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"68311_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17305\/bjbms.2020.4908","volume":"21","author":"S Vrani\u0107","year":"2021","unstructured":"Vrani\u0107, S., Be\u0161lija, S. & Gatalica, Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J. Basic Med. Sci. 21, 1\u20134. https:\/\/doi.org\/10.17305\/bjbms.2020.4908 (2021).","journal-title":"Bosn J. Basic Med. Sci."},{"key":"68311_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101420","volume":"297","author":"YL Chen","year":"2021","unstructured":"Chen, Y. L. et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy. J. Biol. Chem. 297, 101420. https:\/\/doi.org\/10.1016\/j.jbc.2021.101420 (2021).","journal-title":"J. Biol. Chem."},{"key":"68311_CR48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41571-020-00449-x","volume":"18","author":"SH Gohil","year":"2021","unstructured":"Gohil, S. H. et al. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 244\u2013256. https:\/\/doi.org\/10.1038\/s41571-020-00449-x (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68311_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello, C., Morganti, S. & Curigliano, G. Antibody-drug conjugates in solid tumors: A look into novel targets. J. Hematol. Oncol. 14, 20. https:\/\/doi.org\/10.1186\/s13045-021-01035-z (2021).","journal-title":"J. Hematol. Oncol."},{"key":"68311_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-023-11735-z","volume":"23","author":"C Nie","year":"2023","unstructured":"Nie, C. et al. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: A multicenter real-world study. BMC Cancer 23, 1239. https:\/\/doi.org\/10.1186\/s12885-023-11735-z (2023).","journal-title":"BMC Cancer"},{"key":"68311_CR51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128199","author":"LA Koopman","year":"2019","unstructured":"Koopman, L. A. et al. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.128199 (2019).","journal-title":"JCI Insight"},{"key":"68311_CR52","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/acs.molpharmaceut.0c00873","volume":"18","author":"DV Nadkarni","year":"2021","unstructured":"Nadkarni, D. V. et al. Impact of drug conjugation and loading on target antigen binding and cytotoxicity in cysteine antibody-drug conjugates. Mol. Pharm. 18, 889\u2013897. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00873 (2021).","journal-title":"Mol. Pharm."},{"key":"68311_CR53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. Cancer 129, 283\u2013295. https:\/\/doi.org\/10.1002\/cncr.34507 (2023).","journal-title":"Cancer"},{"key":"68311_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters, J. C. et al. Clinical toxicity of antibody drug conjugates: A meta-analysis of payloads. Investig. New Drugs 36, 121\u2013135. https:\/\/doi.org\/10.1007\/s10637-017-0520-6 (2018).","journal-title":"Investig. New Drugs"},{"key":"68311_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68311_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers 6, 38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"68311_CR57","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven, D. C. et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 9, 1039121. https:\/\/doi.org\/10.3389\/fmolb.2022.1039121 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"68311_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/imt-2020-0179","volume":"13","author":"FG Dall'Olio","year":"2021","unstructured":"Dall\u2019Olio, F. G. et al. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A meta-analysis. Immunotherapy 13, 257\u2013270. https:\/\/doi.org\/10.2217\/imt-2020-0179 (2021).","journal-title":"Immunotherapy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68311-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68311-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68311-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:04:29Z","timestamp":1727438669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68311-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68311"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68311-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22357"}}